Merida Biosciences develops Fc-engineered therapeutics that selectively bind and neutralize pathogenic antibodies and target autoreactive B cells, pursuing programs in Graves’ disease, allergy, and primary membranous nephropathy.
meridabio.comPart of: Boston tech scene from Fundable